Ibrutinib (Imbruvica)

Indications

  • Mantle Cell Lymphoma (see Lymphoma, [[Lymphoma]])

Adverse Effects

  • >10% (MCL)
    Increased serum creatinine, 1.5 x ULN (67%)
    Platelets decreased, all grades (57%)
    Diarrhea (51%)
    Hemorrhage (48%)
    Neutrophils decreased, all grades (47%)
    Hemoglobin decreased, all grades (41%)
    Fatigue (41%)
    Musculoskeletal pain (37%)
    Peripheral edema (35%)
    URI infection (34%)
    Nausea (31%)
    Bruising (30%)
    Neutropenia, grades 3 or 4 (29%)
    Dyspnea (27%)
    Constipation (25%)
    Rash (25%)
    Abdominal pain (24%)
    Vomiting (23%)
    Decreased appetite (221%)
    Cough (19%)
    Pyrexia (18%)
    Stomatitis (17%)
    Thrombocytopenia, grades 3 or 4 (17%)
    UTI infection (14%)
    Pneumonia (14%)
    Skin infections (14%)
    Asthenia (14%)
    Muscle spasms (14%)
    Dizziness (14%)
    Sinusitis (13%)
    Headache (13%)
    Dehydration (12%)
    Dyspepsia (11%)
    Petechiae (11%)
    Arthralgia (11%)
    Epistaxis (11%)

  • >10% (CLL)
    Platelets decreased, all grades (71%)
    Diarrhea (63%)
    Bruising (54%)
    Neutrophils decreased, all grades (54%)
    URT infection (48%)
    Hemoglobin decreased, all grades (44%)
    Fatigue (31%)
    Rash (27%)
    Musculoskeletal pain (27%)
    Neutropenia, grades 3 or 4 (27%)
    Pyrexia (25%)
    Peripheral edema (23%)
    Constipation (23%)
    Arthralgia (23%)
    Nausea (21%)
    Stomatitis (21%)
    Sinusitis (21%)
    Dizziness (21%)
    Vomiting (19%)
    Cough (19%)
    Muscle spasms (19%)
    Headache (19%)
    Skin infection (17%)
    Petechiae (17%)
    Decreased appetite (17%)
    Hypertension (17%
    Abdominal pain (15%)
    Oropharyngeal pain (15%)
    Dyspepsia (13%)
    Asthenia (13%)
    Chills (13%)

  • 1-10% (MCL)
    Anemia, grades 3 or 4 (9%)
    Increased serum creatinine, 1.5-3 x ULN (9%)
    Hemorrhage, grades 3 or 4 (5%)
    Secondary primary malignancies (5%)

  • 1-10% (CLL)
    Pneumonia (10%)
    UTI (10%)
    Dyspnea (10%)
    Peripheral neuropathy (10%)
    Second malignancies (10%)
    Anxiety (10%)
    Insomnia (10%)
    Thrombocytopenia, grades 3 or 4 (10%)


References

  • xxx